HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Van Haver, H. Articles by Carton, H. Search for Related Content PubMed PubMed Citation Articles by Van Haver, H. Articles by Carton, H.

Transfer factor therapy in multiple sclerosis

A three-year prospective double-blind clinical trial

Department of Neurology (Drs. Van Haver, Van Hees, Theys, Vervliet, and Carton), University of Leuven; the National MS Center, (Dr. Lissoir, Mrs. Droissart, and Dr. Ketelaer), Melsbroek; and the Red Cross Blood Transfusion Center (Drs. Claeys, Gautama, and Vermylen), Leuven, Belgium.

One hundred five patients with MS were divided into three groups matched for age, sex, and disability, and treated with either placebo, transfer factor prepared from leukocytes of random donors, or transfer factor from leukocytes of family members living with the patients. There were no differences in the three treatment groups for changes in disability, activities of daily living, or evoked potentials. Eighteen months of transfer factor therapy had no effect on gamma-interferon production or natural killer cell activities.

Address correspondence and reprint requests to Dr. Van Haver. Department of Neurology, University of Leuven, Belgium.

Accepted for publication February 4, 1986.